Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MMF and eye disease.

M Zierhut1, N Stübiger, K Siepmann

  • 1Department of Ophthalmology I, University of Tuebingen, Tuebingen, Germany. manfred.zierhut@med.uni-tuebingen.de

Lupus
|April 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Acute unilateral loss of vision after intravitreal injection of a VEGF inhibitor].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2021
Same author

Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel.

The British journal of dermatology·2019
Same author

Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.

Seminars in arthritis and rheumatism·2019
Same author

[Acute unilateral non-traumatic enophthalmus].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2018
Same author

[Intraocular inflammation in multiple sclerosis].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2018
Same author

[Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis].

Zeitschrift fur Rheumatologie·2017
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Mycophenolate mofetil (MMF) is an effective immunosuppressive treatment for various ocular inflammatory disorders, including ocular cicatricial pemphigoid (OCP) and uveitis. MMF demonstrates comparable efficacy to cyclosporine A in preventing graft rejection and shows a favorable side effect profile.

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Immunosuppressive therapies are crucial for managing ocular inflammatory diseases.
  • Individual responses and side effect profiles often limit the use of current immunosuppressants.

Purpose of the Study:

  • To review the efficacy and safety of mycophenolate mofetil (MMF) in treating several ocular inflammatory conditions.
  • To evaluate MMF's role in preventing graft rejection after penetrating keratoplasty (PK).

Main Methods:

  • Systematic review of existing studies on MMF in ocular inflammation.
  • Analysis of controlled trials for graft rejection prevention.
  • Examination of smaller patient group studies for other ocular conditions.

Related Experiment Videos

Main Results:

  • MMF shows comparable efficacy to cyclosporine A in preventing graft rejection post-PK.
  • MMF is highly effective in preventing retinal destruction in experimental uveitis models.
  • Evidence suggests MMF is effective for ocular cicatricial pemphigoid (OCP), uveitis, atopic keratoconjunctivitis (AKC), and scleritis.
  • MMF generally presents a limited spectrum of side effects compared to other immunosuppressives.

Conclusions:

  • Mycophenolate mofetil (MMF) is a promising immunosuppressive agent for diverse ocular inflammatory disorders.
  • MMF offers a potentially safer alternative with comparable efficacy for specific ophthalmic applications.